LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
20 Novembre 2020 - 7:50PM
LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company
targeting the biopharma sector, announced today that it priced its
initial public offering of 7,500,000 shares at $10.00 per share.
The shares will begin trading today on the NASDAQ Capital Market
(“NASDAQ”) under the symbol “LSAQ.”
LifeSci Capital LLC acted as lead book-running manager and
Ladenburg Thalmann & Co. Inc. acted as joint book-running
manager for the offering (the “Underwriters”). The underwriters
have been granted a 45-day option to purchase up to an additional
1,125,000 shares offered by the Company to cover over-allotments,
if any.
The offering is expected to close on or about November 24, 2020,
subject to customary closing conditions.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission
on November 20, 2020. The offering is being made only by means
of a prospectus, copies of which may be obtained from LifeSci
Capital LLC, 250 West 55th Street, 34th Floor #3401, New York, NY
10019, Attn: Syndicate Department, or Ladenburg Thalmann & Co.
Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, Attn:
Syndicate Department. Copies of the registration statement can be
accessed through the SEC's website
at www.sec.gov.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About LifeSci Acquisition II
Corp.LifeSci Acquisition II Corp.
(NASDAQ:LSAQ) is a blank check company formed for
the purpose of entering into a merger, share exchange, asset
acquisition, stock purchase, recapitalization, reorganization, or
other similar business combination with one or more businesses or
entities. The company intends to pursue prospective targets that
are focused on healthcare innovation in North America or Europe.
For more information, please
visit www.lifesciacquisition.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risks and uncertainties. Forward looking statements are
statements that are not historical facts. Such forward-looking
statements, including the successful consummation of the LifeSci
Acquisition II Corp.’s initial public offering, are subject to
risks and uncertainties, which could cause actual results to differ
from the forward looking statements. LifeSci Acquisition II Corp.
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in LifeSci Acquisition II
Corp.’s expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Media ContactKristin Politi, Ph.D.LifeSci
Communications(646) 876-4783kpoliti@lifescicomms.com
LifeSci Acquisition II (NASDAQ:LSAQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
LifeSci Acquisition II (NASDAQ:LSAQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024